Description
Evofosfamide (TH-302) is an anticancer agent that is a hypoxia-activated prodrug that is created by linking the hypoxia-seeking 2-nitroimidazole moiety to the cytotoxic bromo-isophosphoramide mustard (Br-IPM). When evofosfamide is delivered to hypoxic regions of tumors, the DNA cross-linking toxin, Br-IPM, is released leading to cell death.
Evofosfamide (TH-302) is an anticancer agent that is a hypoxia-activated prodrug that is created by linking the hypoxia-seeking 2-nitroimidazole moiety to the cytotoxic bromo-isophosphoramide mustard (Br-IPM). When evofosfamide is delivered to hypoxic regions of tumors, the DNA cross-linking toxin, Br-IPM, is released leading to cell death.
Alternate Name/Synonyms: Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; TH302; TH-302
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 918633-87-1
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₉H₁₆Br₂N₅O₄P
Molecular Weight: 449.04
Cell-Permeable?: Yes
Purity: ≥98%
Solubilities: DMSO
Handling: Protect from air and light
Country of Origin: USA
Tag Line: An anticancer agent
MDL Number: N/A
PubChem CID: 11984561
SMILES: CN1C(=CN=C1[N+](=O)[O-])COP(=O)(NCCBr)NCCBr
InChi: InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)
InChi Key: UGJWRPJDTDGERK-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |